Results for this period
First quarter1 January 2026–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Sales grew, led by the healthcare business, supported by steady performance in the direct-to-consumer business and order growth. Profit margins improved through price revisions, productivity improvements, greater efficiency in advertising and promotional investment, lower logistics costs, sales promotion expenses and sales commission ratios, fixed-cost reductions, and lower personnel expenses.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–31 March 2026 |
| Net Sales | ¥13,197 million (YoY +10.6%) |
| Operating profit | ¥837 million (YoY +35.4%) |
| Ordinary income | ¥782 million (YoY +79.3%) |
| Profit attributable to owners of the parent | ¥-32 million |
| Net income per share | -¥0.23 |
| Equity ratio | End of the current fiscal period 46.4 / End of previous period 42.7 |
| Total assets | ¥70,658 million |
| Net assets | ¥30,799 million |
| Full-year earnings forecast | Net Sales ¥52,000 million (YoY +3.2%) / Operating profit ¥3,200 million (YoY +2.5%) / Ordinary income ¥2,800 million (YoY +18.4%) / Net income Not disclosed |
| Annual Dividend Forecast | ¥2 → ¥0（-100.0%） |
| Segment revenue | Healthcare Business ¥12,189 million (YoY +11.6%) / Biofuels business ¥256 million (YoY +1.3%) / Other Businesses ¥756 million (YoY -0.9%) |
| Segment profit | Healthcare Business ¥1,499 million (YoY +24.6%) / Biofuels business ¥-132 million / Other Businesses ¥-107 million |
| Depreciation and amortization | ¥598 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on reversal of subscription rights to shares ¥0 million / Extraordinary loss Not disclosed |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | No (no eligible attendees) |
| Issued Shares at Period-End | 139,273,056 Shares |
| Treasury Shares at Period-End | 20,918 Shares |
| Factors Behind Changes in Business Performance | Sales grew, led by the healthcare business, supported by steady performance in the direct-to-consumer business and order growth. Profit margins improved through price revisions, productivity improvements, greater efficiency in advertising and promotional investment, lower logistics costs, sales promotion expenses and sales commission ratios, fixed-cost reductions, and lower personnel expenses. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The effects of measures including growth in healthcare business sales, steady performance in the Q'SAI Group's direct-to-consumer business, expansion of orders at the SatisPharma Group, price revisions for core products, productivity improvements, greater efficiency in advertising and promotional investment, lower logistics costs, sales promotion expenses and sales commission ratios, fixed-cost reductions, and lower personnel expenses contributed to the results.